New therapeutic approaches to treating hypertension in pregnancy

Drug Discovery Today

Volumn 17, Issue 23-24, 2012, Pages 1307-1315

  Mate, Alfonso ^a   Vázquez, Carmen M ^a   Leiva, Andrea ^b   Sobrevía, Luis ^b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ALISKIREN; ALPHA TOCOPHEROL; ANGIOGENIC FACTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ARGININE; ASCORBIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARNITINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; HEME OXYGENASE 1; HYDRALAZINE; LABETALOL; MAGNESIUM SULFATE; MATRIX METALLOPROTEINASE INHIBITOR; METHYLDOPA; MICRORNA; N(G),N(G) DIMETHYLARGININE; NIFEDIPINE; NITRIC OXIDE; RENIN INHIBITOR; ROSIGLITAZONE; VASCULOTROPIN 121; VASODILATOR AGENT;

ANTIHYPERTENSIVE THERAPY; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPOXIA; INFLAMMATION; MATERNAL HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLACENTA; PREECLAMPSIA; PREMATURE LABOR; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SEIZURE; VITAMIN SUPPLEMENTATION;

ANTIHYPERTENSIVE AGENTS; DRUG DISCOVERY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; PLACENTA; PREGNANCY;

EID: 84870307495     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.07.004     Document Type: Review

References (67)

1. B. Jim Hypertension in pregnancy: a comprehensive update Cardiol. Rev. 18 2010 178 189
2. E.A. Steegers Pre-eclampsia Lancet 376 2010 631 644
3. C.E. Powe Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease Circulation 123 2011 2856 2869
4. M. Chen, and L. Zhang Epigenetic mechanisms in developmental programming of adult disease Drug Discov. Today 16 2011 1007 1018
5. M.D. Lindheimer Hypertension in pregnancy J. Am. Soc. Hypertens. 2 2008 484 494
6. B.C. Young Pathogenesis of preeclampsia Annu. Rev. Pathol. 5 2010 173 192
7. F.P. McCarthy Animal models of preeclampsia; uses and limitations Placenta 32 2011 413 419
8. L. Sobrevia Review: differential placental macrovascular and microvascular endothelial dysfunction in gestational diabetes Placenta 32 Suppl. 2 2011 159 164
9. A. Leiva Fetoplacental vascular endothelial dysfunction as an early phenomenon in the programming of human adult diseases in subjects born from gestational diabetes mellitus or obesity in pregnancy Exp. Diabetes Res. 2011 2011 349286
10. C. Escudero, and L. Sobrevia A hypothesis for preeclampsia: adenosine and inducible nitric oxide synthase in human placental microvascular endothelium Placenta 29 2008 469 483
11. R. San Martin, and L. Sobrevia Gestational diabetes and the adenosine/l-arginine/nitric oxide (ALANO) pathway in human umbilical vein endothelium Placenta 27 2006 1 10 (Pubitemid 41662874)
12. F. Slaghekke Endogenous inhibitors of nitric oxide and preeclampsia: a review J. Matern. Fetal Neonatal Med. 19 2006 447 452 (Pubitemid 44373615)
13. E. Guzman-Gutierrez Functional link between adenosine and insulin: a hypothesis for fetoplacental vascular endothelial dysfunction in gestational diabetes Curr. Vasc. Pharmacol. 9 2011 750 762
14. P. Casanello Reduced l-arginine transport and nitric oxide synthesis in human umbilical vein endothelial cells from intrauterine growth restriction pregnancies is not further altered by hypoxia Placenta 30 2009 625 633
15. L. Myatt Reactive oxygen and nitrogen species and functional adaptation of the placenta Placenta 31 Suppl. 2010 66 69
16. M. Mohaupt Molecular aspects of preeclampsia Mol. Aspects Med. 28 2007 169 191 (Pubitemid 46843190)
17. K. Kanasaki, and R. Kalluri The biology of preeclampsia Kidney Int. 76 2009 831 837
18. A. Mate The therapeutic prospects of using l-carnitine to manage hypertension-related organ damage Drug Discov. Today 15 2010 484 492
19. B. LaMarca Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia Curr. Opin. Pharmacol. 11 2011 175 179
20. C.C. Zhou Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice Nat. Med. 14 2008 855 862
21. A. Zhou A redox switch in angiotensinogen modulates angiotensin release Nature 468 2010 108 111
22. S. Rana Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia Circulation 125 2012 911 919
23. E.M. George Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications Curr. Opin. Nephrol. Hypertens. 21 2012 157 162
24. C.P. Prieto Hypoxia-reduced nitric oxide synthase activity is partially explained by higher arginase-2 activity and cellular redistribution in human umbilical vein endothelium Placenta 32 2011 932 940
25. S. Sankaralingam Arginase contributes to endothelial cell oxidative stress in response to plasma from women with preeclampsia Cardiovasc. Res. 85 2010 194 203
26. G.D. Anderson, and D.B. Carr Effect of pregnancy on the pharmacokinetics of antihypertensive drugs Clin. Pharmacokinet. 48 2009 159 168
27. M. Moser Hypertension in pregnancy: is it time for a new approach to treatment? J. Hypertens. 30 2012 1092 1100
28. L.A. Magee How to manage hypertension in pregnancy effectively Br. J. Clin. Pharmacol. 72 2011 394 401
29. E.W. Seely, and J. Ecker Clinical practice. Chronic hypertension in pregnancy N. Engl. J. Med. 365 2011 439 446
30. J.G. Umans Antihypertensive treatment J. Roberts, Chesley's Hypertensive Disorders in Pregnancy 3rd edn. 2009 Academic Press 369 387
31. J. Espinoza High fetal plasma adenosine concentration: a role for the fetus in preeclampsia? Am. J. Obstet. Gynecol. 205 2011 485.e24 485.e27
32. C. Escudero, and L. Sobrevia Adenosine plasma levels in the fetoplacental circulation in preeclampsia Am. J. Obstet. Gynecol. 206 2012 e5 e6
33. E.M. George Regulation of sFlt-1 and VEGF secretion by adenosine under hypoxic conditions in rat placental villous explants Am. J. Physiol. Regul. Integr. Comp. Physiol. 299 2010 1629 1633
34. C. Escudero Potential cell signalling mechanisms involved in differential placental angiogenesis in mild and severe pre-eclampsia Curr. Vasc. Pharmacol. 7 2009 475 485
35. K. Rytlewski Effects of oral l-arginine on the foetal condition and neonatal outcome in preeclampsia: a preliminary report Basic Clin. Pharmacol. Toxicol. 99 2006 146 152 (Pubitemid 44213943)
36. F. Facchinetti l-Arginine supplementation in patients with gestational hypertension: a pilot study Hypertens. Pregnancy 26 2007 121 130 (Pubitemid 46649344)
37. M.A. Hladunewich Effect of l-arginine therapy on the glomerular injury of preeclampsia: a randomized controlled trial Obstet. Gynecol. 107 2006 886 895
38. J.M. Sasser Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(omega)-nitro-l-arginine methyl ester hypertensive rats Hypertension 58 2011 197 204
39. E.T. van der Westhuizen Relaxin family peptide receptors - from orphans to therapeutic targets Drug Discov. Today 13 2008 640 651
40. M. Cudmore Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1 Circulation 115 2007 1789 1797 (Pubitemid 46648616)
41. E.M. George Induction of heme oxygenase-1 attenuates sFlt-1-induced hypertension in pregnant rats Am. J. Physiol. Regul. Integr. Comp. Physiol. 301 2011 1495 1500
42. A. Ahmed A new mouse model to explore therapies for preeclampsia PLoS One 5 2010 e13663
43. M.M. Costantine Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia Obstet. Gynecol. 116 2010 114 120
44. K. Kumasawa Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model Proc. Natl Acad. Sci. U. S. A. 108 2011 1451 1455
45. M.J. Cudmore Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta Am. J. Obstet. Gynecol. 206 2012 253.e10 253.e15
46. F.P. McCarthy Peroxisome proliferator-activated receptor-gamma as a potential therapeutic target in the treatment of preeclampsia Hypertension 58 2011 280 286
47. M.G. Olsson Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for alpha1-microglobulin Antioxid. Redox. Signal. 17 2012 813 846
48. E.M. George, and J.P. Granger Mechanisms and potential therapies for preeclampsia Curr. Hypertens. Rep. 13 2011 269 275
49. J.S. Gilbert Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension Hypertension 55 2010 380 385
50. Z. Li Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia Hypertension 50 2007 686 692 (Pubitemid 47442732)
51. R. Thadhani Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia Circulation 124 2011 940 950
52. T.J. Kaitu'u-Lino MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin Am. J. Pathol. 180 2012 888 894
53. S. Kalkunte Vascular IL-10: a protective role in preeclampsia J. Reprod. Immunol. 88 2011 165 169
54. D.A. Enquobahrie Placental microRNA expression in pregnancies complicated by preeclampsia Am. J. Obstet. Gynecol. 204 2011 178.e12 178.e21
55. K. Lahjouji l-Carnitine transport in human placental brush-border membranes is mediated by the sodium-dependent organic cation transporter OCTN2 Am. J. Physiol. Cell Physiol. 287 2004 263 269
56. S.W. Cho, and Y.S. Cha Pregnancy increases urinary loss of carnitine and reduces plasma carnitine in Korean women Br. J. Nutr. 93 2005 685 691
57. I.G. Thiele Increased plasma carnitine concentrations in preeclampsia Obstet. Gynecol. 103 2004 876 880 (Pubitemid 40458987)
58. T.T. Chang Hypoxia-mediated down-regulation of OCTN2 and PPARalpha expression in human placentas and in BeWo cells Mol. Pharm. 8 2011 117 125
59. N.A. Oey l-Carnitine is synthesized in the human fetal-placental unit: potential roles in placental and fetal metabolism Placenta 27 2006 841 846 (Pubitemid 43905930)
60. W.B. Geven Pre-eclampsia in a woman whose child suffered from lethal carnitine-acylcarnitine translocase deficiency BJOG 114 2007 1028 1030 (Pubitemid 47052759)
61. S. Illsinger Preeclampsia and HELLP syndrome: impaired mitochondrial function in umbilical endothelial cells Reprod. Sci. 17 2010 219 226
62. S.H. Seong l-Carnitine-supplemented parenteral nutrition improves fat metabolism but fails to support compensatory growth in premature Korean infants Nutr. Res. 30 2010 233 239
63. M.A. Stasi Propionyl-l-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide production Arterioscler. Thromb. Vasc. Biol. 30 2010 426 435
64. C.C. Zhou Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia J. Immunol. 186 2011 6024 6034
65. J.L. Miguel-Carrasco The role of inflammatory markers in the cardioprotective effect of l-carnitine in L-NAME-induced hypertension Am. J. Hypertens. 21 2008 1231 1237
66. K. Mimura Nicotine restores endothelial dysfunction caused by excess sFlt1 and sEng in an in vitro model of preeclamptic vascular endothelium: a possible therapeutic role of nicotinic acetylcholine receptor (nAChR) agonists for preeclampsia Am. J. Obstet. Gynecol. 202 2010 464.e1 464.e6
67. L.C. Poon First-trimester prediction of hypertensive disorders in pregnancy Hypertension 53 2009 812 818